×
About 48,272 results

QINLOCK (ripretinib) - Health Care Professional Site‎
https://www.qinlockhcp.com/

Learn more about the mechanism of action of QINLOCK. Request more information today. Download the QINLOCK clinical efficacy and safety overview for healthcare professionals. Resources. Support Your Patients. View Dosing Information. FDA Approved. Clinical Data.

Prescription Drug Pricing Transparency Law Comparison Chart
https://www.nashp.org/prescription-drug-pricing-transparency-law-comparison-chart/
The National Academy for State Health Policy (NAHSP)

A number of states have enacted drug pricing transparency laws requiring drug supply chain entities such as manufacturers, pharmacy benefit managers, health plans, and others to report information explaining high price increases and high-priced new drugs. This chart compares states’ transparency laws, each tab provides an overview of required reporting from specific supply chain entities. To le...

TABRECTA™ (capmatinib) - Now Approved - HCP Site‎
https://www.hcp.novartis.com/products/tabrecta/met-exon-14-skipping-mutation-nsclc/efficacy/?site=MTX-1228793GK104516&source=01030&gclid=EAIaIQobChMIqfz855_K6QIVCZezCh1p0gOqEAAYAiAAEgJWYPD_BwE&gclsrc=aw.ds

HCPs, Visit The Official Site For Information About TABRECTA™ As A Treatment Option. See If TABRECTA™ Could Be Right For Your Patients. Full Safety Profile. Patient Co-Pay Program. Mechanism Of Action. Newly FDA Approved. Official HCP Website. Clinical Trial Data.

ASTERO® (lidocaine)
http://genscopharma.com/products/astero/

Astero® is the only FDA-approved prescription hydrogel and 4% Lidocaine HCl for pain associated with wound healing and vasculitis. Available by prescription only, Astero® provides superior wound healing and has a rapid onset of action in 3-5 minutes.

CHILDRENS BENADRYL ALLERGY
https://www.benadryl.com/allergies-in-children

Learn more about children’s BENADRYL® dosing, tips for reducing your child’s allergy symptoms and how to create an allergy action plan."

BRILINTA® (ticagrelor) tablets
https://www.brilintatouchpoints.com/

Official health care professional site for BRILINTA® (ticagrelor) tablets, indicated to reduce the rate of CV death, MI, and stroke in patients with acute coronary syndrome (ACS). Find information about dosage, mechanism of action, and more.

LUMIXYL TRIFECTING NIGHT CREAM
http://envymedical.com/product/trifecting-night-cream-0-2/

Shop Envy Medical for Trifecting Night Cream Anti-Aging Triple Action Overnight Product

EFFACLAR DUO
https://www.laroche-posay.us/effaclar-duo-883140500759.html#q=EFFACLAR+DUO&start=2

DUAL ACTION ACNE TREATMENT: This acne spot treatment reduces the number and severity of acne blemishes and helps clear blackheads and whiteheads. With 5.5% micronized benzoyl peroxide and micro-exfoliating lipo-hydroxy acid, this treatment provides fast, visible results in 3 days.

Digital Health Innovation Action Plan
https://www.fda.gov/downloads/MedicalDevices/DigitalHealth/UCM568735.pdf

FDA’s Center for Devices and Radiological Health (CDRH) puts patients at the forefront of our vision—we are driven by timely patient access to high-quality, safe and effective medical technology.

EXTAVIA (interferon beta-1b)
https://www.extaviahcp.com/

Fingertip Formulary®. Analytics report. Extavia: Percentage of covered lives. https://www.novartisformularyadvisor.com/?action=home. Accessed June 2016.

KYBELLA ® (deoxycholic acid)
http://hcp.mykybella.com/

ABOUT SUBMENTAL FULLNESS · ABOUT KYBELLA · CLINICAL STUDY DESIGN · CLINICAL RESULTS · SAFETY PROFILE · MECHANISM OF ACTION ...

FARXIGA® (dapagliflozin) TABLETS
https://www.farxiga-hcp.com/

FARXIGA® (dapagliflozin) is an SGLT2 inhibitor indicated for adults with type 2 diabetes mellitus. Explore the science behind FARXIGA. Find out more about FARXIGA including dosage, mechanism of action, and whether FARXIGA is right for your patients.

FARYDAK® (panobinostat) CAPSULES
https://www.hcp.novartis.com/products/farydak/multiple-myeloma/

Access the home page for information about FARYDAK® (panobinostat) capsules. Efficacy, response, safety, dosing, mechanism of action, and patient access are discussed. See full Prescribing and Safety Information.

RAYOS (prednisone) delayed-release tablets
https://www.rayosrx.com/hcp/

RAYOS releases the anti-inflammatory action of prednisone ~4 hours after taking a tablet—allowing you to conveniently time the dose to work when your patients need it. Eligible patients pay as little as $0 for every prescription!* Access RAYOS Savings Program co-pay cards for your patients

ENTYVIO (vedolizumab) INJECTION
https://www.entyviohcp.com/

Find ENTYVIO (vedolizumab) clinical data, safety data, dosing, mechanism of action, access & support, and resources. See Important Safety Information and Prescribing Information.

KineretRx.com | About Kineret | For Healthcare Professionals
https://www.kineretrx.com/hcp

Review the mechanism of action of Kineret, a recombinant IL-1 receptor antagonist and learn about the role of IL-1 in RA and NOMID.

OTEZLA® (apremilast) tablets
https://www.otezlapro.com/

Learn about Otezla (apremilast), a treatment for moderate to severe plaque psoriasis or active psoriatic arthritis. Review the mechanism of action (MOA), the clinical trial program, efficacy data, and safety. Access educational materials for your patients and information about prescribing and starting patients on Otezla.

TYSABRI® (natalizumab)
https://www.tysabrihcp.com

Learn about TYSABRI (natalizumab), including clinical experiences, mechanism of action, potential adverse reactions, and HCP resources. See full ISI & Boxed Warning.

VYZULTA (latanoprostene bunod ophthalmic solution)
https://www.vyzulta.com/hcp/

VYZULTA DELIVERS A DUAL MECHANISM OF ACTION. FOR THE REDUCTION OF IOP IN GLAUCOMA Patients1. Vyzulta Banner. One molecule. TWO OUTFLOW PATHWAYS. PROVEN IOP Reduction.1-3*. *In studies up to 12 months' duration, the IOP-lowering effect was up to 7.5 to 9.1 mmHg, in patients with an

Filgotinib
https://www.glpg.com/filgotinib

Mar 6th, 2019 - Filgotinib is a highly selective JAK1 inhibitor, discovered and developed by Galapagos using its target and drug discovery technology platform. In more than 1,600 patient years of rheumatoid arthritis (RA) and Crohn's disease clinical study experience, filgotinib has shown a rapid onset of action, potentially best-in-class efficacy and favorable findings on safety and tolerability. From a regul...